Apollo Hospitals Enterprise profit and loss

Latest FY26

Revenue: ₹25,229cr+15.8% on FY25
EBITDA: ₹3,769cr+24.7% on FY25
Net profit: ₹2,003cr+33.1% on FY25
EPS: ₹135.04+34.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	26,430	25,229	21,794	19,059	16,612	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	200	192	200	106	90.3
	26,630	25,420	21,994	19,166	16,703
	3,130	3,041	2,754	2,454	2,284
	10,509	10,056	8,557	7,385	6,315
	−13.3	−21.6	−1.1	−33.5	−24.5
	3,084	3,000	2,769	2,494	2,144
	462	450	459	449	381
	897	876	758	687	615
	5,712	5,383	4,693	4,369	3,845
	23,779	22,785	19,988	17,805	15,559
	4,010	3,769	3,022	2,391	2,050
	3,113	2,893	2,264	1,704	1,434
Profit
	2,852	2,635	2,006	1,361	1,144
	−19.2	−19.2	0.0	1.9	0.0
	2,832	2,616	2,006	1,363	1,144
	715	629	526	437	406
	−9.8	28.9	7.7	8.7	−150
	705	658	534	446	256
	44.7	44.9	33.0	18.0	−43.2
	2,172	2,003	1,505	935	845
	2,127	1,958	1,472	917	888
	56.4	58.4	−6.3	−10.4	−13.3
	2,228	2,061	1,499	925	831
	2,090	1,942	1,446	899	819
	82.5	61.0	59.2	36.4	25.5
Per share
	₹145.34	₹135.04	₹100.56	₹62.50	₹56.97
	₹145.26	₹134.94	₹100.56	₹62.50	₹56.97
Other comprehensive income — detail
	56.4	58.4	−6.3	−10.4	−13.3
	59.8	61.9	−8.6	−14.2	−20.7
	6.4	6.4	−1.7	−3.6	−5.2
	—	6.4	−1.7	−3.6	−5.2
	3.0	2.9	0.6	0.2	2.2
	2,145	1,999	1,441	888	806
	83.2	61.7	57.9	36.2	25.2
Per share — as-filed variants
	₹145.34	₹135.04	₹100.56	₹62.50	₹56.97
	₹145.26	₹134.94	₹100.56	₹62.50	₹56.97
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	12,805	12,153	10,484	9,254	8,038
	48.4%	48.2%	48.1%	48.6%	48.4%
Adjusted (ex-exceptional items) — derived
	2,852	2,635	2,006	1,361	1,144
	−19.2	−19.2	0.0	1.9	0.0
	2,186	2,017	1,505	934	845
	₹146.30	₹136.01	₹100.56	₹62.41	₹56.97

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APOLLOHOSP₹8,137.00

Apollo Hospitals Enterprise Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersFORTIS MAXHEALTH MEDANTA SUNPHARMA CIPLA DRREDDY DIVISLAB TORNTPHARMMcap ₹1.17L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	16,612.5	19,059.2	21,794.0	25,228.5	26,429.9
Other Income	90.3	106.3	200.3	191.6	200.2
Total Income	16,702.8	19,165.5	21,994.3	25,420.1	26,630.1
Expenses
+ Cost of Materials Consumed	2,283.8	2,454.1	2,754.4	3,040.8	3,129.7
+ Purchases of Stock-in-Trade	6,315.0	7,384.9	8,556.7	10,056.4	10,508.7
+ Changes in Inventories	-24.5	-33.5	-1.1	-21.6	-13.3
+ Employee Benefit Expense	2,143.8	2,493.7	2,769.2	3,000.3	3,083.5
+ Finance Costs	380.8	449.4	458.5	449.6	461.7
+ Depreciation & Amortisation	615.2	687.0	757.5	876.1	896.5
+ Other Expenses	3,844.8	4,369.3	4,693.0	5,383.3	5,711.8
Total Expenses	15,558.9	17,804.9	19,988.2	22,784.9	23,778.6
EBITDA	2,049.6	2,390.7	3,021.8	3,769.3	4,009.5
EBIT	1,434.4	1,703.7	2,264.3	2,893.2	3,113.0
Profit
PBT before Exceptional Items	1,143.9	1,360.6	2,006.1	2,635.2	2,851.5
+ Exceptional Items	0.0	1.9	0.0	-19.2	-19.2
Pretax Income	1,143.9	1,362.5	2,006.1	2,616.0	2,832.3
+ Current Tax	405.9	436.8	526.3	629.3	714.8
+ Deferred Tax	-149.7	8.7	7.7	28.9	-9.8
Tax Expense	256.2	445.5	534.0	658.2	705.0
+ Share of Associates & JVs	-43.2	18.0	33.0	44.9	44.7
Net Income	844.6	935.0	1,505.1	2,002.7	2,172.0
+ Net Income — Continuing Ops	887.7	917.0	1,472.1	1,957.8	2,127.3
+ Other Comprehensive Income	-13.3	-10.4	-6.3	58.4	56.4
Total Comprehensive Income	831.3	924.6	1,498.8	2,061.1	2,228.4
Net Income to Common	819.1	898.6	1,445.9	1,941.7	2,089.5
Minority Interest	25.5	36.4	59.2	61.0	82.5
Per Share
Basic EPS	56.97	62.50	100.56	135.04	145.34
Diluted EPS	56.97	62.50	100.56	134.94	145.26
Other Comprehensive Income — detail
+ Other Comprehensive Income	-13.3	-10.4	-6.3	58.4	56.4
+ Items NOT to be Reclassified to P&L	-20.7	-14.2	-8.6	61.9	59.8
+ Tax on Items NOT to be Reclassified	-5.2	-3.6	-1.7	6.4	6.4
+ Tax on Items NOT to be Reclassified — alt tag	-5.2	-3.6	-1.7	6.4	—
+ Items to be Reclassified to P&L	2.2	0.2	0.6	2.9	3.0
Comprehensive Income — Owners of Parent	806.1	888.4	1,440.9	1,999.4	2,145.2
Comprehensive Income — Non-controlling Interests	25.2	36.2	57.9	61.7	83.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	56.97	62.50	100.56	135.04	145.34
Diluted EPS — Continuing Operations	56.97	62.50	100.56	134.94	145.26
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	8,038.2	9,253.7	10,484.0	12,152.9	12,804.8
Gross Margin %	48.39	48.55	48.10	48.17	48.45
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,143.9	1,360.6	2,006.1	2,635.2	2,851.5
− Exceptional Items (reconciliation)	0.0	1.9	0.0	-19.2	-19.2
Net Income Adj (tax-effected)	844.6	933.7	1,505.1	2,017.1	2,186.4
EPS Adj	56.97	62.41	100.56	136.01	146.30
Other Filed Concepts — mapped but not yet placed in the schedule
Pat After Tax	887.5	—	—	—	—
Face Value	5.00	5.00	10.00	5.00	5.00
Paid Up Equity Capital	71.9	71.9	71.9	71.9	71.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 145%.